Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-4021586
Advancement of Additional Cardiac Myosin Inhibitor Expands Specialty Cardiovascular PortfolioSOUTH SAN FRANCISCO, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Cytokinetics,...
Read more